Spend on cancer per patient in England 2006 - 2007

£8,818

Compare this with other PCTs: highest amount spent was £17,028, lowest was £5,182, and average PCT spend per cancer patient was £8,437.

Exceptional funding for cancer treatment

The following information was requested from the PCT under the Freedom of Information Act.

Written protocols
The PCT has written protocols to assess exceptional requests for cancer treatment.

Cancer treatments funded by PCT following exceptional requests

From 01 April 2007 to 20 June 2008, the following cancer treatments were approved:

• Erbitux (cetuximab) x 6
• Tarceva (erlotinib) x 1
• Sutent (sunitinib) x 1
• Capecitabine/oxiplatin combination therapy x 1
• Dasatinib x 1
• Taxotere (docetaxel) x 6
• Gemcitabine x 2
• Alimta (pemetrexed) x 2
• Taxol x 1
• Temozolomide x 8
• Herceptin (trastuzumab) x 16 in 2006-2007 - now included in contract
• Bortezomib (Velcade) x 2

Cancer treatments not funded by PCT following exceptional requests

From 01 April 2007 to 20 June 2008, the following cancer treatments were refused:

• Bevacizumab (Avastin) x 4
• Erbitux (cetuximab) x 2
• Tarceva (erlotinib) x 4
• Sutent (sunitinib) x 7
• Sorafenib (Nexavar) x 1
• Capecitabine x 1
• Dasatinib x 2
• Taxotere (docetaxel) x 3
• Gemcitabine x 2
• Alimta (pemetrexed) x 1